Shilpa Medicare
BSE:530549 Community- 1 Narratives written by author
- 1 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
WA
Consensus Narrative from 2 Analysts
Upcoming Commercial Supply Of Tranexamic Acid And UDCA Will Tap New Markets
Key Takeaways Shilpa Medicare's oncology and non-oncology segments are poised for revenue growth through new product launches and market expansions. Diversification in CDMO and promising developments in biologics could provide stable revenue streams and enhance market share.
View narrative₹1.21k
FV
44.1% undervalued intrinsic discount32.54%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
24 days ago author updated this narrative